Heritable hypofibrinolysis, mediated by 4G/4G homozygosity for the PAI-1 gene, is an independent significant, potentially reversible risk factor for pregnancy complications, probably acting through thrombotic induction of placental insufficiency.
How common is PAI-1 4G 4G?
TABLE 2. PAI-1 Genotypes and PAI-1 Allele Frequencies in Stroke Cases and Controls
| Study A | Study B | |
|---|---|---|
| Stroke Patients | Stroke Patients | |
| PAI-1 allele frequency | ||
| 4G | 0.66 | 0.61 |
| 5G | 0.34 | 0.39 |
•14-Jul-2005
Is PAI-1 a blood clotting disorder?
Plasminogen activator inhibitor type 1 (PAI1) deficiency is a rare bleeding disorder that causes excessive or prolonged bleeding due to blood clots being broken down too early. PAI1 is a protein in the body needed for normal blood clotting.
What is 4G 4G Pai?
The 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene as an independent risk factor for placental insufficiency, which triggers fetal hemodynamic centralization. Ceska Gynekol.
What is plasminogen inhibitor PAI-1 4G 5G?
Background and Purpose— Plasminogen activator inhibitor type 1 (PAI-1) is the main inhibitor of fibrinolysis, and high levels may increase the risk of cardiovascular disease. The 4G/5G polymorphism affects PAI-1 gene transcription with lower levels of plasma PAI-1 in the presence of the 5G allele.
What is PAI-1 deficiency?
Complete plasminogen activator inhibitor 1 deficiency (complete PAI-1 deficiency) is a disorder that causes abnormal bleeding. In people with this disorder, bleeding associated with injury can be excessive and last longer than usual.
What is Hypofibrinolysis?
Hypofibrinolysis causes impaired clot break-down, leading to thrombosis. This can be caused by the production of auto-antibodies against plasminogen activators (such as tPA and uPA), or against fibrinolytic receptor components (such as annexin).
How do I lower my PAI-1 level?
In vitro studies have shown that statins increase tPA and decrease PAI-1 levels. This effect involves geranylgeranyl transferase inhibition. The mechanism by which statins treatment reduces PAI-1 is different from those that increase t-PA (16).